Stibbe advised Lundbeck on the acquisition of Prexton Therapeutics BV for an amount of up to EUR 905 million.
Lundbeck (listed on the Copenhagen Stock Exchange in Denmark) is a global pharmaceutical company specialising in psychiatric and neurological disorders with a focus on Alzheimer's disease, depression, Parkinson's disease and schizophrenia.